AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00688740
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT00688740
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous
Trial: NCT00095576
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Trivalent MRKAd5 HIV-1 gag/pol/nef in three 1 mL doses at Day 1, Week 4, and Week 26 administered intramuscularly.
Trial: NCT01096004
Drug: AZD4017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension, 1200mg, once daily, for 10 days
Trial: NCT01096004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03859219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion
Trial: NCT06192420
Drug: Traumeel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g of gel three times daily for 7days (+1 day visit window)
Trial: NCT06192420
Drug: Diclofenac sodium gel 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g of gel three times daily for 7days (+1 day visit window)
Trial: NCT06192420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g of gel three times daily for 7days (+1 day visit window)
Trial: NCT00392574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT00924092
Drug: (Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00358878
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration once daily
Trial: NCT02407119
Drug: 7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Clarithromycin 500 mg bid for 7 days, Amoxicillin 1,000 mg bid for 7 days.
Trial: NCT02407119
Drug: Placebo, Omeprazole or Rabeprazole, Clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Placebo for clarithromycin 500 mg bid for 7 days, Placebo for amoxicillin 1,000 mg bid for 7 days.
Trial: NCT02323048
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sugar pill)
Trial: NCT01027676
Drug: Study treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250mg/QD plus vorinostat D1\~7 \& D15-21 / QD q 4weeks
Trial: NCT01217892
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01098890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered every 12 hours for a maximum of 5 doses.
Trial: NCT04345614
Drug: Auxora
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Auxora will be given at 2.0 mg/kg (1.25 mL/kg) on Day 1 and then 1.6 mg/kg (1.0 mL/kg) on Days 2 and 3. All doses of Auxora will be administered intravenously (IV) over 4 hours.
Trial: NCT04345614
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given at 1.25 mL/kg on Day 1 and then 1.0 mL/kg on Days 2 and 3. All doses of placebo will be administered intravenously over 4 hours.
Trial: NCT00947531
Drug: 0.9% Saline Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00415636
Drug: IC83/LY2603618
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. Dose finding study: dose is escalated after a minimum of 6 participants receive 40 mg/m\^2.
Trial: NCT00415636
Drug: IC83/LY2603618
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
Trial: NCT00415636
Drug: IC83/LY2603618
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 105 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
Trial: NCT00415636
Drug: IC83/LY2603618
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
Trial: NCT00415636
Drug: IC83/LY2603618
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 195 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
Trial: NCT00331721
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT03914690
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
Trial: NCT01737905
Drug: Epinephrine HFA-MDI (E004)
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose 125 mcg/inhalation, 2 inhalations
Trial: NCT01737905
Drug: Placebo-HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose 0 mcg/inhalation, 2 inhalations
Trial: NCT02769104
Drug: AC*4-T*4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTX800mg/m2 d1+Anthracyclines75mg/m2 d1, every 3 weeks\*4 cycles, be sequential with Docetaxel 75mg/m2 d1, every 3 weeks\*4cycles
Trial: NCT04438824
Drug: INCMGA00012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCMGA00012: 500 mg IV (flat dose) q28 days (+/- 7 days in each cycle)
Trial: NCT03879382
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300mg/m2/d
Trial: NCT02081703
Drug: AYX1 Injection 660 mg / 6 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mL solution for intrathecal injection with 660 mg of AYX1
Trial: NCT02081703
Drug: AYX1 Injection 1100 mg / 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL solution for intrathecal injection with 1100 mg of AYX1
Trial: NCT02081703
Drug: Placebo Injection 6 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
Trial: NCT02081703
Drug: Placebo Injection 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
Trial: NCT04099901
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be treated with a daily dose of placebo, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).
Trial: NCT02239003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02630641
Drug: Gonadotropin-releasing Hormone (GnRH) agonist therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a non-interventional study. Thus, investigators are free to choose GnRH agonist therapy product, and modalities of administration in accordance with local Summary of Product Characteristics.
Trial: NCT00648414
Drug: Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow, while samples collected
Trial: NCT00648414
Drug: Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tourniquet applied just below patch application site and above blood draw site, while samples collected
Trial: NCT00648414
Drug: Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tourniquet applied just above patch application site, while samples collected
Trial: NCT00648414
Drug: Duragesic 25 mcg/h + Clinical Procedure 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
Trial: NCT00648414
Drug: Duragesic 25 mcg/h + Clinical Procedure 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tourniquet applied just below patch application site and above blood draw site, while samples collected
Trial: NCT00648414
Drug: Duragesic 25 mcg/h + Clinical Procedure 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tourniquet applied just above patch application site, while samples collected
Trial: NCT03038620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
Trial: NCT01233947
Drug: AFP464
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycle
Trial: NCT01233947
Drug: AFP464 + Faslodex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycles and faslodex administered per the package label
Trial: NCT02480049
Drug: Asmakast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet contains 10 mg of montelukast
Trial: NCT03430999
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01283984
Drug: AZD2115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, oral inhalation (nebuliser solution)
Trial: NCT01283984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, oral inhalation (nebuliser solution)
Trial: NCT02665377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02766855
Drug: Cysteamine
RxNorm normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were asked to use topical cysteamine 0.55% eye drops every 2 hours while awake to both eyes.
Trial: NCT01506726
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salsalate 750mg tablet 1 pill bid for one month followed by Salsalate 750mg tablets 2 pills (1500mg) twice a day for a further 5 months (total duration of treatment will be 6 months)
Trial: NCT01506726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet - one pill twice daily for one month, followed by 2 pills twice daily for a further 5 months. Total duration of treatment is 6 months
Trial: NCT01753752
Drug: Chitosan- N- Acetylcysteine eye drops
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00224549
Drug: irbesartan, amlodipine and hydrochlorothiazide
RxNorm normalized name: irbesartan, amlodipine and hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irbesartan, amlodipine and hydrochlorothiazide
Trial: NCT01753752
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04147286
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo
Trial: NCT01969578
Drug: Cisplatin + Doxorubicin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03792269
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03336606
Drug: MEDI0562
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical resection of tumor
Trial: NCT04293432
Drug: Drugs, Generic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All drugs having ≥10 TdP cases reported in the FAERS database
Trial: NCT03589833
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate 7.5-15mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 15mg (max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 5 mg per week were applied to all participants.
Trial: NCT01841476
Drug: POL6326
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02399228
Drug: 0.25% EISO mouth rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A mouth rinse to be used three times a day during the course of radiation and/or chemotherapy to prevent or minimize oral mucositis
Trial: NCT00934180
Drug: Zofran®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 8 mg ODT
Trial: NCT01050114
Drug: onaBoNT-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: onaBoNT-A will be the active formulation. Each vial of onaBoNT-A Purified Neurotoxin Complex, Formulation No. 9060X, contains: 100 units (U) of Clostridium botulinum toxin type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. One U corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice. A 0.9% sterile saline (without preservative) for injection will be used as diluent for onaBoNT-A.~Each treatment session will be administered as 20 injections each of 1 mL (10U/ml), evenly distributed into the bladder.
Trial: NCT00420706
Drug: SCA-136
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03296982
Drug: Saline sham
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01990690
Drug: anti oxidant omega 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gelatineous capsule (Sedico medical company) each capsule contains:~* Fish oil (30) % (Eicosapentaenoic acid (EPA) 18 % / Docosahexaenoic acid (DHA) 12 % ) natural source of Omega 3 Fatty acids.~* Wheat germ oil (Tocopherol: N.N.T. 0.22 %) which is rich and natural source of Vitamin E (protects the oils from oxidation. besides its well known that requirements of vitamin E increases with increased dietary amounts of polyunsaturated fatty acids).~Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks.
Trial: NCT01357681
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02185183
Drug: Alequel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alequel
Trial: NCT03037749
Drug: Placebo beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo beverage measured to mimic the smell and taste of the alcohol beverage.
Trial: NCT00195728
Drug: Hydrocodone/Acetaminophen on Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets twice daily
Trial: NCT00931541
Drug: AZD6088
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution. Each subject will receive a single-dose of AZD6088.
Trial: NCT00931541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution. Each subject will receive a single-dose of placebo.
Trial: NCT01394185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive placebo
Trial: NCT02458729
Drug: 0.9% Normal Saline (intraoperative)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Normal Saline 20ml administered intravenously five minutes before deflation of the tourniquet
Trial: NCT02458729
Drug: 0.9% Normal Saline (3 hours after operation)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Normal Saline 20ml administered intravenously 3 hours after operation
Trial: NCT02804763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion, 0,9% saline
Trial: NCT04110145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, capsules, mixed with water and administered orally, once daily in fasted state
Trial: NCT00953628
Drug: 250 mcg recombinant HCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bolus 250 mcg for ovulation triggering in IVF patients
Trial: NCT04019002
Drug: Hyperpolarized 13C Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given at 0.43 milliliters/kilogram body weight of a 250 millimolar (mM) solution via intravenous injection over a period of about 1 minute once prior to each research magnetic resonance imaging procedure.
Trial: NCT00621283
Drug: RG1068 (Synthetic Human Secretin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
Trial: NCT00775658
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day
Trial: NCT01871649
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be started at a dosage of 15 mg/week orally and, if well tolerated, increased to 20mg/week at week 4 and 25mg/week at week 8 of the trial. If well tolerated, the maximum dose of 25 mg/week will be sustained until end of study (week 50). Folic acid 5 mg/week will be administered orally one day after the MTX intake.
Trial: NCT03907202
Drug: Daily injection of KBP/placebo for up to 28 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sub-cutaneous injection of KBP-089/Placebo into a lifted skin fold of the abdominal wall.The injection will be administered in the morning before breakfast.
Trial: NCT02759510
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypotension (systolic BP \<80% of baseline) will be treated with intravenous boluses of norepinephrine 2 μg.
Trial: NCT04200963
Drug: IK-175
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be administered IK-175 PO daily for every 21-day treatment cycle during the Single Agent Treatment dose escalation or for every 28-day treatment cycle during the Single Agent dose expansion.
Trial: NCT01300637
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical-appearing pill of placebo
Trial: NCT00626236
Drug: SPN-810
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule taken three times a day
Trial: NCT00626236
Drug: SPN-810
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule taken TID
Trial: NCT00939185
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zithromax was dispensed according to the Summary of Product Characteristics (SPC) as either a tablet or suspension. Zithromax was administered as a total dose of 30 mg/kg which was given as single daily doses of 10 mg/kg for 3 days, or as a 5 day dose starting with 10 mg/kg on Day 1, then 5 mg/kg on Days 2-5.
Trial: NCT00190957
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02845414
Drug: CD133KDEL (dCD133KDEL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive dCD133KDEL at the assigned dose level via a 30-minute intravenous infusion on days 1, 3, 5, 8, 10 and 12 (total of 6 doses) of a 28-day cycle.
Trial: NCT01302886
Drug: BHQ880
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00568009
Drug: SLV320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1, 2.5, 5, 10 and 20 mg twice daily and placebo group. Duration of treatment 84 days
Trial: NCT02485184
Drug: Anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation therapy includes heparin and warfarin.
Trial: NCT01655056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02299245
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: different dose of rosuvastatin treatment
Trial: NCT01342055
Drug: Apetrol ES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sequences of administered drugs
Trial: NCT00388609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, Oral, Once daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
Trial: NCT00321932
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (Zometa®) will be administered after randomization (but within 28 days prior to transplant) and at 3 and 6 months after the transplant for a total of 3 doses. The dose of Zometa will be 4 mg intravenous in 100 ml of sterile 0.9% sodium chloride, United States Pharmacopeia (USP), or 5% dextrose, USP infused over a minimum of 15 minutes for patients with a calculated creatinine clearance of ≥60 mL/min. The drug may be administered through a peripheral or a central intravenous line.
Trial: NCT00734032
Drug: SB480848 80mg EC Tablet
RxNorm normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet once a day
Trial: NCT00734032
Drug: SB480848 Placebo Tablet
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet once a day
Trial: NCT02295865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo either 30 mg tablet or 3 mg tablet will be administered orally.
Trial: NCT00135304
Drug: Sensipar®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet hydrochloride
Trial: NCT02989857
Drug: AG-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally
Trial: NCT02989857
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally